De-resuscitation Informed by Ultrasound for Patients With Sepsis (DRI-US)
Sepsis, Septic Shock, Sepsis, Severe
About this trial
This is an interventional treatment trial for Sepsis
Eligibility Criteria
Inclusion Criteria:
1. Must be suspected by the treating physician to have sepsis as the primary cause of their acute illness as exhibited by 2 or more of the following Systemic Inflammatory Response Syndrome (SIRS) criteria:
- Temperature of > 38 C or < 36 C
- Heart rate of > 90/min
- Respiratory rate of > 20/min or PaCO2 < 32 mm Hg
- White blood cell count > 12000/mm3 or < 4000/mm3 or >10% immature bands. 2. Known or suspected infection at the time of screening 3. Admission to the ICU for <24 hours
Since approximately 12% of patients ultimately diagnosed with sepsis do not meet SIRS criteria, SIRS negative patients will be eligible for the study if the treating physician makes a clinical diagnosis of severe sepsis or septic shock.
Exclusion Criteria:
- Patients with conditions that may interfere with portal Doppler assessments such as cirrhosis or portal thrombosis
- Patients with severe chronic kidney disease (estimated glomerular filtration rate<15 mL/min per 1.73 m2 calculated using the Modified Diet in Renal Disease formula).
- Age < 18 years
- Active atrial fibrillation or atrial flutter
- Hemodynamic instability due to active hemorrhage
- Acute cerebral vascular event
- Acute coronary syndrome (excluding elevated troponin thought to be from demand ischemia)
- Acute pulmonary edema
- Status asthmaticus
- Drug overdose
- Injury from burn or trauma
- Status epilepticus
- Indication for immediate surgery
- Received CPR within 24 hours of enrollment
- Pregnancy
- Incarceration.
Sites / Locations
- The Miriam HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
VExUS-Guided Arm
Usual Care Control Arm
Will receive 24 hour fluid balance target based on daily VExUS score.
Treating team will be blinded to results of daily VExUS score and will set 24 hour fluid balance target based on usual care.